Rosa Kim, MD
Ophthalmology · Houston, TXNPI 1558469460
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 32.2% of the total. 2025 is the largest year on record at $1,382, more than ten times the $59 reported in 2019.
Across 60 payments — averaging $44.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$859
- Bausch & Lomb Americas Inc.$402
- AbbVie$246
- Astellas Pharma US Inc$188
- Carl Zeiss Meditec USA, Inc.$139
- Apellis Pharmaceuticals, Inc.$134
- plus $701 from 12 others
Across 4 payments — averaging $1763.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eyepoint US, Inc.$7K
What the payments were for
- Speaking & faculty fees$863%
- Food & beverage$2,58297%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 17 | $859 |
| Bausch & Lomb Americas Inc. | 3 | $402 |
| AbbVie(2 entities) | 9 | $246 |
| Astellas Pharma US Inc | 3 | $188 |
| Carl Zeiss Meditec USA, Inc. | 1 | $139 |
| Apellis Pharmaceuticals, Inc. | 6 | $134 |
| Alcon | 1 | $117 |
| Regeneron | 1 | $92 |
| Genentech USA, Inc. | 3 | $87 |
| Notal Vision, Inc. | 2 | $86 |
| Biogen | 3 | $74 |
| Mallinckrodt Hospital Products Inc. | 3 | $69 |
| Alimera Sciences, Inc. | 2 | $45 |
| Boston Scientific | 2 | $40 |
| Coherus Oncology, Inc. | 1 | $28 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Amgen | 1 | $21 |
| Novartis | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,668 in reported general payments places this provider in the 55th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 367 | $22,321 |
| Loteprednol Etabonate | 57 | $13,366 |
| Ketorolac Tromethamine | 314 | $6,961 |
| Brimonidine Tartrate | 295 | $5,207 |
| Bromfenac Sodium | 27 | $5,132 |
| Difluprednate | 26 | $3,047 |
| Atropine Sulfate | 39 | $2,254 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 128 | $1,562 |
| Acetazolamide | 20 | $1,535 |
| MoxifloxacinMoxifloxacin Hcl | 33 | $921 |
| Diclofenac Sodium | 63 | $894 |
| Prednisone | 117 | $838 |
| Latanoprost | 88 | $835 |
| Dorzolamide Hcl | 53 | $825 |
| ValacyclovirValacyclovir Hcl | 28 | $790 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Houston
- John MichelettiHouston$916K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- Stephen SladeHouston$530K
- David BrownHouston$514K
- Shaheen KavoussiHouston$480K
- Elvia CansecoHouston$322K
- Bac NguyenHouston$319K
- Douglas KochHouston$308K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.